Description: Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health diseases and other endocrine-related disorders. Its lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. The company also intends to develop RVT-602, an oligopeptide kisspeptin analog, for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. was founded in 2016 and is based in Hamilton, Bermuda. Myovant Sciences Ltd. operates as a subsidiary of Roivant Sciences Ltd.
Home Page: myovant.com
MYOV Technical Analysis
11-12 St. James’s Square
London,
SW1Y 4LB
United Kingdom
Phone:
44 20 7400 3351
Officers
| Name | Title |
|---|---|
| Mr. David C. Marek | CEO & Director |
| Mr. Uneek Mehra | Principal Financial Officer |
| Ms. Lauren Merendino | Chief Commercial Officer |
| Mr. Matthew Lang J.D. | Gen. Counsel & Corp. Sec. |
| Mr. Albert Liao | Director of Corp. Communications |
| Ms. Ann Tomlin | Sr. VP of HR |
| Mr. Bryan Selby | Sr. VP of Product Devel. |
| Dr. Juan Camilo Arjona Ferreira M.D. | Chief Medical Officer |
| Dr. Andria Langenberg M.D. | Head of Drug Safety & Pharmacovigilance |
| Mr. Jeffrey D. Nornhold | Sr. VP of Pharmaceutical Operations & Devel. |
Exchange: NYSE
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 70.0114 |
| Price-to-Sales TTM: | 7.7963 |
| IPO Date: | 2016-10-27 |
| Fiscal Year End: | March |
| Full Time Employees: | 579 |